On April 7, 2026, London-based Vira Health launched the Vira Health Member Zone — a global employee health benefits platform covering hormonal health, fertility, pregnancy, postpartum, parenting, menopause, and men's health, available in more than 100 countries and 20+ languages. The launch is a strategic expansion beyond the company's existing direct-to-consumer offering Stella, a specialist menopause telehealth service currently live in the UK, US, and South Africa. TELUS Health was named as one of the first distribution partners, offering the Member Zone through its Employee Assistance Programme.

Why It Matters

The Vira launch lands in the same window as Maven Clinic's April 14 expansion (Oura integration, Color Health partnership), the UK government's £1.5M FemTech Challenge Fund (April 15), and a steady drumbeat of Q1 femtech funding rounds. Together those signals confirm that 2026 is the year employer-paid reproductive and hormonal health benefits move from niche perk to mainstream HR line-item — globally, not just in the US. For sextech and sexual wellness brands, the strategic implication is clear: integration into employer benefits platforms is becoming a viable distribution channel that does not require Meta/Google ad approval, payment-processor cooperation, or mainstream retail shelf space. Vira's 100-country/20-language footprint is the new high-water mark.

The platform stitches together expert-led educational content, online events, virtual appointments, care advocacy, and a specialist referral network into a single multilingual stack — meaningful differentiation in the femtech/employer-benefits market, where most direct competitors (Maven Clinic, Carrot, Progyny, Gennev) operate primarily in English-speaking markets and lean heavily on US clinical infrastructure. Vira's coverage of men's health alongside women's reproductive and hormonal care also expands the buyer pool from "women's-health benefits" line items to general workforce wellness.

Vira Health was co-founded by Andrea Berchowitz and Dr. Rebecca Love and previously raised €10.9M ($12M) Series A in March 2022 to scale its menopause-specific work. Berchowitz framed the launch around employer ROI: 30% of women consider quitting jobs due to menopause symptoms and 57% would consider changing jobs for better reproductive health benefits — both statistics that have driven the recent surge in employer interest in dedicated reproductive-health benefits programs. The Member Zone's broader-scope positioning also lets Vira compete for global enterprise contracts where buyers need a single vendor across geographies rather than a patchwork of country-specific point solutions.

Sources

Update — 2026-05-02

Initial entry — story first created.